CYTLIMIC Inc. was established by NEC Corporation (NEC; TSE: 6701) to promotes the development and application of therapeutic cancer peptide vaccines discovered using NECs unique advanced Artificial Intelligence (AI) technology.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
NECs _immune function prediction technologyÓ combines machine learning and experimentation to discover potential new substances. Only a few biological tests are needed to predict potential new drugs from an enormous number of chemical substances. This is accomplished with a high degree of accuracy, within a short timeframe, and at low cost.
NEC has been engaged in collaborative research since 2014 with Yamaguchi University and Kochi University, and in clinical research with Yamaguchi University, resulting in the discovery of a peptide vaccine that promises to be effective in the treatment of hepatoma and esophageal cancer and is compatible with the genetic profile of approximately 85% of Japans population.
In Jan 2017, CYTLIMIC, signed a Material Transfer Agreement (MTA) with Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), to provide IMP321 for a formulation development of new pre-clinical and clinical development study to be conducted by CYTLIMIC. The development will be funded by CYTLIMIC and the MTA will be revenue generating for Prima.